|
Daily Medical Update
Peripheral Artery Disease (Claudication, ABI screening)
Monday, March 2, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Journal of the American Heart Association (2025) - Randomized Controlled Trial
Key Findings
- Gamification plus automated coaching increased daily steps versus control by 1,074 steps during follow-up (95% CI 133 to 2,015; P=0.03).
- Intervention-phase benefit trended positive at +920 steps/day (95% CI -22 to 1,861), indicating clinically meaningful activity gains despite borderline significance during active treatment.
📋 Practice Implication: Offer PAD patients a structured remote step program (wearable + weekly goals + behavioral nudges) when supervised exercise therapy is unavailable, rather than relying on generic walk-goal advice.
|
Diabetes, Obesity & Metabolism (2026) - Systematic Review/Meta-Analysis
Key Findings
- In PAD cohorts, GLP-1 receptor agonist-based therapy was associated with fewer major adverse limb events (OR 0.66) and lower all-cause mortality (OR 0.55).
- Revascularization need was reduced in PAD cohorts (OR 0.85), and broader T2D populations also showed fewer amputations (OR 0.58).
📋 Practice Implication: When choosing glucose-lowering therapy for T2D plus PAD, preferentially consider GLP-1RA agents to potentially reduce limb complications, not just HbA1c.
|
JACC: Cardiovascular Interventions (2026) - Randomized Trial Secondary Analysis
Key Findings
- Atherectomy was not associated with better major adverse limb outcomes versus non-atherectomy endovascular strategies (adjusted HR 1.30, 95% CI 0.92 to 1.84).
- In technically successful cases, atherectomy was linked to higher MALE risk (adjusted HR 1.51, 95% CI 1.03 to 2.22).
📋 Practice Implication: For PCP counseling before referral, frame atherectomy as a non-default option and ask specialists to justify its use based on lesion specifics rather than presumed superiority.
|
European Journal of Vascular and Endovascular Surgery (2026) - Randomized Trial Secondary Analysis
Key Findings
- Higher GLASS stage predicted worse MALE-free survival and more reinterventions after endovascular therapy, indicating poorer durability in complex anatomy.
- For GLASS stage 2 to 3 disease, open bypass showed fewer major reinterventions (HR 0.24 to 0.37) and fewer amputations (HR 0.57 to 0.62) than endovascular-first treatment.
📋 Practice Implication: Escalate earlier to vascular surgery discussion in complex PAD anatomy, because bypass may outperform endovascular-first strategies for limb outcomes in advanced disease patterns.
|
British Journal of Surgery (2025) - Meta-Analysis of RCTs
Key Findings
- Pooled hazard-ratio analysis showed higher long-term mortality with supervised exercise therapy alone versus early revascularization (HR 1.83, 95% CI 1.10 to 3.04).
- Exercise-first pathways reduced immediate procedures but had high crossover (34.8%) and more later revascularization (OR 2.30, 95% CI 1.71 to 3.11).
📋 Practice Implication: If claudication remains materially function-limiting after a defined exercise trial, shorten time to vascular referral instead of repeatedly extending conservative therapy without reassessment.
|
|
Recent PAD evidence suggests three practical shifts for primary care: stronger use of scalable activity interventions when supervised exercise is inaccessible, tighter medication selection that may reduce limb events in diabetics, and more selective referral for invasive strategies rather than defaulting to atherectomy. New trial and meta-analysis signals also support anatomy-informed referral planning and nuanced risk-factor management.
|
|